| Document |
Document Title |
|
WO/2019/053617A1 |
The invention is directed to substituted salicylamide derivatives. Specifically, the invention is directed to compounds according to FormµLa (I): wherein R, R1,P, X, Y, and Z are as defined herein; or a pharmaceutically acceptable salt ...
|
|
WO/2019/043139A1 |
A compound of formula (I): which inhibits the activity of one or more KATs of the MYST family, i.e., TIP60, KAT6B, MOZ, HBO1 and MOF.
|
|
WO/2019/033969A1 |
Disclosed are a eutectic of telmisartan and hydrochlorothiazide, a preparation method therefor and the use thereof. In the eutectic, the molar ratio of telmisartan to hydrochlorothiazide is 1:1. The eutectic of telmisartan and hydrochlor...
|
|
WO/2019/031981A1 |
The present invention relates to novel hepatitis delta virus (HDV) entry inhibitors, to a novel pharmaceutical composition, and to a method for treating HDV infection and co-infection of HDV and hepatitis B virus (HBV). The present hepat...
|
|
WO/2019/013981A1 |
The present teachings relate to a fluoro-containing compound, a composition thereof, a method of using the compound or the composition in treating a disease, and a method of preparing the compound. In a particular example, the compound i...
|
|
WO/2019/003143A1 |
Provided are IDO inhibitor compounds of Formula I and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases. F...
|
|
WO/2018/234808A1 |
The present invention relates to compounds of formula (I). The compounds maybe used to modulate the Stimulator of Interferon Genes (STING) protein and thereby treat diseases such as cancer and microbial infections.
|
|
WO/2018/230528A1 |
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...
|
|
WO/2018/228552A1 |
The present invention relates to a composition comprising zinc thiazole particles and a preparation method therefor. The composition is composed of particles, in which the mass fraction of the weight of the zinc thiazole component occupy...
|
|
WO/2018/224455A1 |
The invention relates to cyclopropyl compounds of formula (I), wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use fo...
|
|
WO/2018/204987A1 |
Compounds are provided which are inhibitors of the CAXII enzyme. Due to the interaction between CAXII and Pgp, such compounds may be useful in lowering the chemoresistance of a cancer allowing for co-administration with existing anti-can...
|
|
WO/2018/202694A1 |
The present invention refers to compounds of the following formula (I) or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions containing them and to a process for the preparation of said compounds: Formula (I), whe...
|
|
WO/2018/196768A1 |
The present invention relates to the field of medical chemistry, and relates to a heterocyclic compound serving as a PD-L1 inhibitor. Specifically, the present invention relates to a compound represented by formula A, or an isomer, pharm...
|
|
WO/2018/193297A1 |
The present invention provides compounds which are modulators of RORϒ and their use for the treatment of diseases or conditions mediated by RORϒ. Further, the present invention relates to processes of preparing such compounds, their ta...
|
|
WO/2018/183699A1 |
Methods and materials for providing corrosion protection for atomically thin materials are described. In some embodiments, an atomically thin material may have a coating that includes one or more alkyl amine species. The coating may cove...
|
|
WO/2018/178384A1 |
The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic h...
|
|
WO/2018/178057A1 |
A method of improving plant safety and/or reducing phytotoxicity and/or reducing plant necrosis whilst combating, preventing or controlling phytopathogenic diseases, which comprises applying to a phytopathogen, to the locus of a phytopat...
|
|
WO/2018/170275A1 |
The present invention provides a compound having the structure:, or a pharmaceutically acceptable salt or ester thereof, and a method of treating a subject afflicted with a pain, a depressive disorder, a mood disorder, an anxiety disorde...
|
|
WO/2018/160618A1 |
Substituted hydroquinones, 1,4-quinones, catechols, 1,2-quinones, anthraquinones, and anthrahydroquinones are disclosed herein. The substituted hydroquinones and catechols have the formula: while the substituted 1,4-quinones or 1,2-have ...
|
|
WO/2018/157813A1 |
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of sphingosine 1-phosphate subtype 1 (S1P1), and in particular relates to compounds as shown in formula (I) or pharmaceutically acc...
|
|
WO/2018/159834A1 |
Provided are a donor-acceptor type compound having a novel structure and an application of the donor-acceptor type compound. This enamine compound is represented by general formula (1) (in the formula: R1 represents an electron-accepting...
|
|
WO/2018/140599A1 |
Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein B, Z, Ra, Rb, Rc, R1, L, L1 ...
|
|
WO/2018/131690A1 |
[Problem] To provide a novel agrochemical, especially a novel herbicide. [Solution] A ketone or oxime compound represented by formula (1), and a herbicide which contains this compound. (In the formula, B represents B-1 or B-2; Q represen...
|
|
WO/2018/122325A1 |
The present invention pertains to a system of collaborative modifiers that are assembled into a multi molecule complex in vivo within a cell using bioorthogonal chemical reactions. The system of the invention is composed of multiple bind...
|
|
WO/2018/116073A1 |
24859-P4PCT ABSTRACT 1, 2, 3-Thiadiazole compounds and their use as crop protecting agent The present invention relates to 1,2,3-thiadiazole compounds of the formula (I), wherein R1, R2, T and Z have the meanings as defined in descriptio...
|
|
WO/2018/116107A1 |
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases ...
|
|
WO/2018/111619A1 |
Pharmaceutical compositions for treating or mitigating glaucoma are described, the compositions comprising several separate components for an improved effect. Methods for fabricating the compositions and using them are also described.
|
|
WO/2018/108791A1 |
The present application relates to thiadiazole compounds of formula (I), in which A, B, E, and Q have the meanings provided in the specification, compositions containing such compounds, their use for controlling animal pests including ar...
|
|
WO/2018/102921A1 |
Herein presented are gold nanoparticles (AuNPs) used for the transport of medications to mucous membranes. The AuNPs are ultra-stable in that they withstand freeze-drying and heating treatments without noticeable change in their structur...
|
|
WO/2018/106284A1 |
This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or condit...
|
|
WO/2018/093694A1 |
Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also ...
|
|
WO/2018/089402A1 |
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...
|
|
WO/2018/081384A1 |
The present disclosure relates to compounds of formula I which inhibit NaV1.7, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (I)
|
|
WO/2018/072602A1 |
The invention provides a compound of formula I: or a pharmaceutically acceptable salt thereof, wherein the variables X, Y1-Y5, R1, R2, R3, R4, and Het have the meaning as described herein, and compositions containing such compounds and m...
|
|
WO/2018/071327A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2018/064119A1 |
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof.
|
|
WO/2018/062978A1 |
The present invention relates to a novel heteroaryl compound, an enantiomer, a diastereomer or a pharmaceutically acceptable salt thereof, and an antiviral composition comprising the same as an active ingredient. The novel compounds repr...
|
|
WO/2018/051252A2 |
An object of the present invention is to provide an amide compound or a salt thereof that controls a mite. The present invention provides an amide compound represented by Formula (1) : or a salt thereof, wherein R1 represents C1-6 alkyl ...
|
|
WO/2018/051255A1 |
The present invention relates to cyclic substituted 1,3,4-oxadiazole and thiadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signaling pathway and/or for treatment of disorders by inhibiting an...
|
|
WO/2018/051254A1 |
The present invention relates to cyclic substituted-1,2,4-oxadiazole compounds of formula (I) and their use to inhibit the programmed cell death 1 (PD1) signalling pathway and/or for treatment of disorders by inhibiting an immunosuppress...
|
|
WO/2018/041768A1 |
The invention relates to novel organic semiconducting (OSC) compounds containing one or more 1,3-dithiolo[5,6-f]benzo-2,1,3-thiadiazole ("DTBTz") or 1,3-dithiolo[6,7-g]quinoxaline ("DTQ") units or derivatives thereof, to methods for thei...
|
|
WO/2018/033654A1 |
The present invention relates to new hole-transporting materials (HTMs) and optoelectronic and/or electrochemical devices comprising the new hole-transporting materials. In some aspects, the HTMs comprise a core based on thienothiophene,...
|
|
WO/2018/029150A1 |
The invention relates to compounds acting as agonists of G-protein coupled receptor 120 (GPR120) and/or 40 (GPR40), and having formula (I). Said compounds are useful in the treatment of diseases or disorders modulated by GPR120 and/or GP...
|
|
WO/2018/028557A1 |
The present invention relates to a series of tricyclic compounds and the use thereof as receptor agonists of 1-phosphate sphingosine 1 subtype (S1P1), and in particular to the compounds shown in formula (I), and tautomers or pharmaceutic...
|
|
WO/2018/011747A1 |
The present invention provides compounds which are modulators of RORγ and their use for the treatment of diseases or conditions mediated by RORγ. Further, the present invention relates to processes of preparing such compounds, their ta...
|
|
WO/2017/219083A1 |
The present invention relates to novel compounds which active HIV expression in latently infected cells. More particularly, the invention relates to pharmaceutical compositions comprising the novel compounds and their use in activating H...
|
|
WO/2017/202376A1 |
A sulfamide compound and a use thereof in preparing pain killers, which specifically relates to compounds as shown in formula (I) and formula (II), tautomers thereof or pharmaceutically acceptable salts thereof.
|
|
WO/2017/167315A1 |
Provided are an anthracenyl organic dye and a preparation method therefor. The organic dye has the structure shown in formula (I) or formula (II), wherein Ra, Rb and R2-1 – R2-4 are defined in the present document. The organic dye is p...
|
|
WO/2017/165256A1 |
The present disclosure relates to compounds of formula (I) that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly ...
|
|
WO/2017/160922A1 |
Disclosed herein are compounds of Formula (I), methods of synthesizing compounds of Formula (I), and methods of using compounds of Formula (I) as an analgesic.
|
